Suvaxyn PRRS MLV
Authorised
This medicine is authorised for use in the European Union
porcine respiratory and reproductive syndrome virus, live
MedicineVeterinaryAuthorised
- Application under evaluation
- CVMP opinion
- European Commission decision
Overview
Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website
Suvaxyn PRRS MLV : EPAR - Medicine overview
English (EN) (81.94 KB - PDF)
First published: Last updated:
български (BG) (93.36 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
español (ES) (81.97 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
čeština (CS) (93.99 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
dansk (DA) (83.34 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Deutsch (DE) (82.76 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
eesti keel (ET) (82.18 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
ελληνικά (EL) (93.76 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
français (FR) (82.44 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
hrvatski (HR) (92.27 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
íslenska (IS) (83.29 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Gaeilge (GA) (83.57 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
italiano (IT) (82.29 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
latviešu valoda (LV) (94.29 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
lietuvių kalba (LT) (94.03 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
magyar (HU) (94.15 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Malti (MT) (95.95 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Nederlands (NL) (82.05 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
norsk (NO) (82 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
polski (PL) (95.62 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
português (PT) (83.01 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
română (RO) (94.17 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
slovenčina (SK) (94.08 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
slovenščina (SL) (82.27 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Suomi (FI) (81.54 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
svenska (SV) (82.05 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Product information
Suvaxyn PRRS MLV : EPAR - Product Information
English (EN) (81.49 KB - PDF)
First published: Last updated:
български (BG) (91.78 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
español (ES) (81.51 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
čeština (CS) (92.48 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
dansk (DA) (82.05 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Deutsch (DE) (81.72 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
eesti keel (ET) (81.22 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
ελληνικά (EL) (91.79 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
français (FR) (81.63 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
hrvatski (HR) (91.56 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
íslenska (IS) (81.52 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Gaeilge (GA) (81.36 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
italiano (IT) (81.76 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
latviešu valoda (LV) (92.14 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
lietuvių kalba (LT) (92.19 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
magyar (HU) (92.76 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Malti (MT) (93.86 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Nederlands (NL) (81.15 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
norsk (NO) (81.52 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
polski (PL) (93.22 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
português (PT) (82.53 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
română (RO) (91.73 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
slovenčina (SK) (81.75 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
slovenščina (SL) (81.76 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Suomi (FI) (81.11 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
svenska (SV) (81.47 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Suvaxyn PRRS MLV : EPAR - All Authorised presentations
English (EN) (81.94 KB - PDF)
First published: Last updated:
български (BG) (93.36 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
español (ES) (81.97 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
čeština (CS) (93.99 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
dansk (DA) (83.34 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Deutsch (DE) (82.76 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
eesti keel (ET) (82.18 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
ελληνικά (EL) (93.76 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
français (FR) (82.44 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
hrvatski (HR) (92.27 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
íslenska (IS) (83.29 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Gaeilge (GA) (83.57 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
italiano (IT) (82.29 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
latviešu valoda (LV) (94.29 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
lietuvių kalba (LT) (94.03 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
magyar (HU) (94.15 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Malti (MT) (95.95 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Nederlands (NL) (82.05 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
norsk (NO) (82 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
polski (PL) (95.62 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
português (PT) (83.01 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
română (RO) (94.17 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
slovenčina (SK) (94.08 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
slovenščina (SL) (82.27 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Suomi (FI) (81.54 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
svenska (SV) (82.05 KB - PDF)
First published: 21/09/2017Last updated: 17/10/2024
Product details
- Name of medicine
- Suvaxyn PRRS MLV
- Active substance
- Modified live porcine respiratory and reproductive syndrome virus
- International non-proprietary name (INN) or common name
- porcine respiratory and reproductive syndrome virus, live
Authorisation details
- EMA product number
- EMEA/V/C/004276
Assessment history
Suvaxyn PRRS MLV : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (81.94 KB - PDF)
First published: Last updated:
CVMP post-authorisation summary of positive opinion for Suvaxyn PRRS MLV (VRA-0011-G)
AdoptedReference Number: EMA/CVMP/265921/2024
English (EN) (146.72 KB - PDF)
First published:
CVMP post-authorisation summary of positive opinion for Suvaxyn PRRS MLV
AdoptedReference Number: EMA/CVMP/40684/2023
English (EN) (135.14 KB - PDF)
First published:
Suvaxyn PRRS MLV : EPAR - Scientific conclusions and grounds for amendment of the summary of product characteristics and package leaflet - Annex IV
English (EN) (152.09 KB - PDF)
First published:
български (BG) (200.73 KB - PDF)
First published: 09/09/2020
español (ES) (150.75 KB - PDF)
First published: 09/09/2020
čeština (CS) (171.97 KB - PDF)
First published: 09/09/2020
dansk (DA) (153.24 KB - PDF)
First published: 09/09/2020
Deutsch (DE) (155.96 KB - PDF)
First published: 09/09/2020
eesti keel (ET) (156.47 KB - PDF)
First published: 09/09/2020
ελληνικά (EL) (191.58 KB - PDF)
First published: 09/09/2020
français (FR) (155.26 KB - PDF)
First published: 09/09/2020
hrvatski (HR) (171.89 KB - PDF)
First published: 09/09/2020
íslenska (IS) (153.32 KB - PDF)
First published: 09/09/2020
italiano (IT) (149.76 KB - PDF)
First published: 09/09/2020
latviešu valoda (LV) (189.91 KB - PDF)
First published: 09/09/2020
lietuvių kalba (LT) (174.83 KB - PDF)
First published: 09/09/2020
magyar (HU) (187.96 KB - PDF)
First published: 09/09/2020
Malti (MT) (199.01 KB - PDF)
First published: 09/09/2020
Nederlands (NL) (156.52 KB - PDF)
First published: 09/09/2020
norsk (NO) (152.77 KB - PDF)
First published: 09/09/2020
polski (PL) (187.54 KB - PDF)
First published: 09/09/2020
português (PT) (153.07 KB - PDF)
First published: 09/09/2020
română (RO) (179.69 KB - PDF)
First published: 09/09/2020
slovenčina (SK) (190.2 KB - PDF)
First published: 09/09/2020
slovenščina (SL) (187.03 KB - PDF)
First published: 09/09/2020
Suomi (FI) (147.4 KB - PDF)
First published: 09/09/2020
svenska (SV) (151.26 KB - PDF)
First published: 09/09/2020
Suvaxyn PRRS MLV-V-C-4276-II-0004/G : EPAR - Assessment report - Variation
Adopted
English (EN) (81.49 KB - PDF)
First published: Last updated:
CVMP post-authorisation summary of positive opinion for Suvaxyn PRRS MLV
AdoptedReference Number: EMA/CVMP/199498/2019
English (EN) (68.43 KB - PDF)
First published:
News on Suvaxyn PRRS MLV
Topics
This page was last updated on